Trials / Completed
CompletedNCT01046539
Phase 1 Study to Evaluate RDC-0313 Coadministered With Buprenorphine to Opioid-Experienced Healthy Adults
A Phase 1 Study to Evaluate the Pharmacodynamics of RDC-0313 Coadministered With Buprenorphine to Opioid-Experienced Healthy Adults
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- Sponsor
- National Institute on Drug Abuse (NIDA) · NIH
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
This is a single site, double-blind, randomized, placebo-controlled, crossover study to assess the pharmacodynamics (PD) of RDC-0313 coadministered with buprenorphine in 12 healthy, opioid-experienced, non-treatment-seeking subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RDC-0313 + Buprenorphine | 1 and 4 mg (1 dose for each) + 8 mg |
| DRUG | Placebo | 0 mg |
Timeline
- Start date
- 2010-01-01
- Primary completion
- 2010-03-01
- Completion
- 2010-07-01
- First posted
- 2010-01-12
- Last updated
- 2017-01-11
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01046539. Inclusion in this directory is not an endorsement.